Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 171.20K | 154.70K | 229.50K | 146.40K | 136.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 371.70K | 163.00K | 241.80K | 168.50K | 168.70K |
| Operating Income | -371.70K | -163.00K | -241.80K | -168.50K | -168.70K |
| Income Before Tax | -341.70K | -203.80K | -432.10K | -226.50K | -172.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -341.70K | -203.80K | -432.10K | -226.50K | -172.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -341.70K | -203.80K | -432.10K | -226.50K | -172.40K |
| EBIT | -371.70K | -163.00K | -241.80K | -168.50K | -168.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 44.79M | 44.79M | 40.50M | 39.79M | 39.79M |
| Average Diluted Shares Outstanding | 44.79M | 44.79M | 40.50M | 39.79M | 39.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |